收费全文 | 13921篇 |
免费 | 1288篇 |
国内免费 | 255篇 |
耳鼻咽喉 | 76篇 |
儿科学 | 190篇 |
妇产科学 | 212篇 |
基础医学 | 595篇 |
口腔科学 | 145篇 |
临床医学 | 2735篇 |
内科学 | 1339篇 |
皮肤病学 | 220篇 |
神经病学 | 330篇 |
特种医学 | 432篇 |
外国民族医学 | 1篇 |
外科学 | 1105篇 |
综合类 | 1185篇 |
一般理论 | 3篇 |
预防医学 | 2876篇 |
眼科学 | 137篇 |
药学 | 2945篇 |
38篇 | |
中国医学 | 501篇 |
肿瘤学 | 399篇 |
2025年 | 2篇 |
2024年 | 222篇 |
2023年 | 455篇 |
2022年 | 603篇 |
2021年 | 860篇 |
2020年 | 892篇 |
2019年 | 841篇 |
2018年 | 787篇 |
2017年 | 793篇 |
2016年 | 737篇 |
2015年 | 706篇 |
2014年 | 1051篇 |
2013年 | 1461篇 |
2012年 | 963篇 |
2011年 | 791篇 |
2010年 | 652篇 |
2009年 | 566篇 |
2008年 | 537篇 |
2007年 | 472篇 |
2006年 | 445篇 |
2005年 | 348篇 |
2004年 | 243篇 |
2003年 | 172篇 |
2002年 | 158篇 |
2001年 | 123篇 |
2000年 | 80篇 |
1999年 | 75篇 |
1998年 | 58篇 |
1997年 | 46篇 |
1996年 | 69篇 |
1995年 | 44篇 |
1994年 | 28篇 |
1993年 | 21篇 |
1992年 | 34篇 |
1991年 | 19篇 |
1990年 | 12篇 |
1989年 | 11篇 |
1988年 | 14篇 |
1987年 | 12篇 |
1986年 | 13篇 |
1985年 | 9篇 |
1984年 | 9篇 |
1983年 | 7篇 |
1982年 | 5篇 |
1981年 | 2篇 |
1980年 | 6篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1975年 | 2篇 |
1973年 | 1篇 |
Areas covered: The understanding of the potential mechanisms of action of pharmaceutically active substances contained in nutraceuticals that may improve health and reduce the risk of pathological conditions while enhancing overall well-being is the challenge for nutraceuticals to be considered as a preventive and therapeutic efficient tool in facing some diseases.
Expert commentary: It is of utmost importance to have a proper and unequivocal definition of nutraceuticals and a shared regulation. Nevertheless, there is a lack of clear information and, often, the claimed health benefits may not be properly substantiated by safety and by efficacy in vivo data, which can induce false expectations and miss the target for a product to be effective, as claimed. 相似文献
Background
Hospitalization can contribute to insomnia in many patients and is usually treated symptomatically. However, sedative/hypnotic misuse is associated with complications in this population, especially in the elderly. Such complications include dizziness, falls and over-sedation. Due to the implicit dangers, widespread use of these drugs for insomnia, particularly in older patients, has been discouraged by many hospitals. The aim of this study was to review and evaluate prescribing patterns and to optimize the use of the sedative/hypnotic agents through daily pharmacy interventions at a community hospital.Methods
This was a biphasic before and after study. Data on sedative/hypnotic use was collected retrospectively for a 2-month period and a sample of 100 patients was randomly selected for analysis. A 2-month prospective phase followed, in which daily orders were reviewed by one pharmacy resident and recommendations made to discontinue any unnecessary, newly prescribed sedative/hypnotic orders when appropriate. Finally, results of both phases were compared for any differences in patient demographics, being prescribed more than one sedative/hypnotic, and complications documented.Results
During the prospective phase, pharmacist interventions led to the discontinuation of 25% of a total of 97 sedative/hypnotic orders in 97 patients. The number of patients receiving more than one sedative/hypnotic agents in the intervention group was significantly lower than the retrospective control group (15 Vs. 34, P?=?0.0026). The incidence of complications was not significantly different between the control and intervention groups for the following: over-sedation, falls and delirium (p?=?0.835, p?=?0.185, p?=?0.697, respectively).Conclusion
This study suggests that the use of sedative/hypnotics in the inpatient units (excluding the critical care unit), is somewhat prevalent, and many patients may be on more than one sedative/hypnotic, which could potentially cause cumulative harm. During the intervention phase, 25% of the total in-hospital orders for sedative/hypnotics were discontinued following recommendations made by a pharmacist, and significantly lower number of patients receiving duplicate sedative/hypnotics was noted. Further efforts should be implemented to avoid unnecessary sedative/hypnotic initiation in hospitalized patients, and to ensure monitoring by pharmacists is optimized. 相似文献Areas covered: in this review we present information about the development and the use of budesonide MMX and we provide data about its mechanism of action as well as, pharmacodynamics and pharmacokynetics. Moreover, we present the available literature data about the efficacy and, mainly, the safety of budesonide-MMX.
Expert opinion: budesonide-MMX is a new therapeutic option in mild-to-moderate UC patients. Its good safety profile in clinical trials undoubtedly represents a strength for a possible wide use in clinical practice, mainly if it will be confirmed by post-marketing data. Other indications, such as treatment of colonic Crohn’s disease, could theoretically be considered, if sustained by reliable scientific data. 相似文献
Areas covered: This review aims to describe the chemistry and pharmacology of LDX, as well as the clinical trials investigating the efficacy and safety of this medication for the management of BED.
Expert opinion: LDX is the first medication with United States Food and Drug Administration approval for the treatment of BED. It is an inactive prodrug of d-amphetamine that extends the half-life of d-amphetamine to allow for once daily dosing. D-amphetamine acts primarily to increase the concentrations of synaptic dopamine and norepinephrine. Metabolism of LDX to d-amphetamine occurs when peptidases in red blood cells cleave the covalent bond between d-amphetamine and l-lysine. D-amphetamine is then further metabolized by CYP2D6. Excretion is primarily through renal mechanisms. In clinical trials, LDX demonstrated statistical and clinical superiority over placebo in reducing binge eating days per week at doses of 50 and 70 mg daily. Commonly reported side effects of LDX include dry mouth, insomnia, weight loss, and headache, and its use should be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia or coronary artery disease. As with all CNS stimulants, risk of abuse needs to be assessed prior to prescribing. 相似文献